Ipatasertib Mechanism of Actio

1
Ipatasertib Mechanism of Actio

• https//www.creative-biolabs.com/adc

2
Ipatasertib

• Also known as GDC-0068, is a strong
  ATP-competitive pan-AKT inhibitor. It was
  initially derived during the screening and
  optimization process of a series of
  6,7-dihydro-5H-cyclopentadpyrimidine compounds.

3
Akt inhibitor

• Ipatasertib shows a powerful inhibition of all
  protein kinase B (Akt) isoforms but a weak
  suppression towards other members of the protein
  kinase family.

• Lorem ipsum dolor sit amet, consectetur
  adipisicing elit, sed do eiusmod tempor
  incididunt ut labore et dolore mag

4
LOREM IPSUM DOLOR
Lorem ipsum dolor sit amet, consectetur
adipisicing elit.
5
A
Ipatasertib Mode of Action(MOA)
6
A
Ipatasertib Mode of Action(MOA)

• Akt, an abbreviated name for protein kinase B
  (PKB), is a serine/threonine-specific protein
  kinase that plays a key role in the PI3K/Akt
  pathway as a regulator for a number of biological
  processes, including glucose metabolism, cell
  differentiation, and transcription. The
  mechanisms of the Akt pathway in tumorigenesis
  are complicated. On one hand, the activated Akt
  contributes to tumor anti-apoptotic activities
  through the inhibition of mitochondrial
  cytochrome c release or the regulation of other
  downstream effectors, including Bcl-2 family
  proteins, FOXO transcription factors and MDM2.

7

• ADCs are composed of cytotoxic agents conjugated
  to monoclonal antibodies that target antigens
  differentially overexpressed on tumor cells. The
  strong cytotoxic agents are expected to induce
  cell death after being internalized into the
  tumor cell and released by various mechanisms.
  Studies have proven that ipatasertib was highly
  efficacious in a variety of tumor models and
  cancer cell lines.

8

• Creative Biolabs is a leader in antibody
  engineering, modification, and production. With
  years of accumulative work, we have established
  an advanced DrugLnk platform to provide highly
  customized strategies for antibody-drug
  conjugates (ADCs) and other targeted antibody
  therapeutics development using ipatasertib
  (GDC-0068) and derivatives as payloads.

9
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
10
THANK YOU